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Abstract
The general method for synthesis the q6-(arene)-triscarbonyl-chromium(0) complexes
was modified and applied for preparation of q6-(anisole)-triscarbonyl-chromium(0) and the
study of its analgesic activity was undertaken. A significant analgesic activity was observed
after intraperitoneal injection, in Wistar rats. Two doses (30 and 50 mg/Kg of the body
weight) of q6-(anisole)- triscarbonyl-chromium(0) were injected and the analgesic activity was
evaluated by the Hot Plate Test method. They showed a significant analgesic effect in
comparison with the control group and the group treated with dipyrone standard, but not so
high when compared with the group treated with morphine standard. Overall, it was observed
that the q6-(anisole)- triscarbonyl-chromium(0) was easily obtained by the modified synthetic
method and was effective in increasing the pain threshold.
Introduction
Arene triscarbony chromium complexes have been known since the fifties and have
been extensively studied .6. The most common method for their preparation is based on the
reaction between hexacarbonyl chromium and arenes. Nevertheless, various problems are
encountered. Some organometallic chromium reagent is lost from the reaction medium by
sublimation 3, while its low level of reactivity requires the use of high boiling point solvents
and/or long reaction times.
Toma and his co-workers observed that yields are low, due to incomplete reaction,
when low boiling point solvents are used. However, when high boiling point solvents are
used, yields are also reduced due to decomposition 4. Many solvents may be used: they
include excess of arene, dioxane, acetone, esters, alkanes, amines, ethers, nitriles etc7".
Classical, but now obsolete techniquesemployed autoclaves1, sealed vessels
6 etc. and
special glassware (Strohmeir apparatus)8..
The most used procedure is that of Mahaffy and Pauson with dibutyl ether/THF as
solvent, under reflux. Toma and his co-workers modified this method using decalin/butyl
acetate4’8, dibutyl ether/butyl acetate, pure decalin, pure butyl acetate, or alkyl formates
as solvent5’7.
To the best of our knowledge, neither qe-(anisole)- triscarbonyl-chromium(0) nor any
other organometallic compound have been screened for analgesic activity.
It is convenient at this point to make some general on analgesic activity.
The pain is part of a defensive reaction against dysfunction of the organism or
imbalance in its functions, as well as against potentially dangerous stimulus. Analgesia by
increase of the pain threshold may be induced by electrical stimulation 12, or, more easily, by
drugs.
There are many drus to reduce pain and a few have been used for centuries. They
21 include morphine, dipyrone‘, aspirin and other salicylates . However, we are not aware of
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The present work reports a modified method for synthesis of q6-(arene)-triscarbonyl-
chromium(0)complexes, represented by the preparation of q e-(anisole)-triscarbonyl-
chromium(0), together with a report on it’s analgesic activity.
Materials and Methods
Experimental
Synthesis of q6-(Arene)-Triscarbonyl Chromium(0) complexes:
Chromium hexacarbonyl, Cr(CO)e (Aldrich) was purified by dissolution in hexane,
filtration through an alumina (Brockmann, activity I) column and evaporation of the solvent
in a stream of nitrogen.
Ethyl acetate (reagent), butyl acetate (Aldrich), dibutyl ether (Aldrich) were refluxed
for two hours over anhydrous potassium carbonate (to remove acidic impurities), then twice
distilled.
Representative Preparation: qe-(Anisole)-triscarbonyl chromium(0)
Chromium hexacarbonyl (1.1 g, 5 mmol) and anisole (0.7g, 7 mmol) was dissolved in
5 mL of dibutyl ether and mL of butyl acetate or ethyl acetate was added. The mixture was
protected from light and deaerated by bubbling with a very slow stream of N and then
refluxed using a long Liebig condenser. The sublimed Cr(CO)6 was returned to the flask with
a glass rod, and the bubbling of the N continued during all the reflux period, for easily
removal of the formed carbon monoxide.
The reflux was continued until no more sublimate appeared at the drop of the
condenser (5-6 hours). After this time, the mixture was cooled and the excess of reagent and
solvents were removed at 40 60o under vacuum, and the residue dissolved in acetone,
filtered through silica (Merck, 60) in a small column, then eluted with acetone. Acetone was
partially removed under vacuum. Hexane was added, and the mixture cooled in freezer
during 12 hours. The precipitate qe-(anisole)-triscarbonyl chromium(0) was isolated in the
form of air stable yellow crystals, m.p. 83 C (literature, 84 85 C3). Yields: 74 % (using ethyl
acetate) and 86 % (using butyl acetate). With the same procedure, some other q-(Arene)-
Triscarbonyl Chromium(0) complexes were prepared (see Results and Discussion)
Analgesic Activity Evaluation Method:
Animals
Male Wistar rats were used, weighing 170g approximately and divided into groups of
five animals. The animals were supplied from the Central for Animal Care of University of
Franca. The animals were maintained in cages, with water and feeding "ad libitum."
Algesimetric Test: Hot- Plate
The hot plate method, modified for rats was used6This method utilises an
aluminium plate maintained at 51+1C, by means of water from a thermostatic water bath
An acrylic box measuring 24 x 18 x 18 cm was placed on the plate to impede the escape of
animals.
The act of licking the hind paws was observed as a response, registering the elapsed
time from the moment that the animal was placed on the hot plate until the response was
obtained
7 (latency time).
To avoid lesions in the animals paws and consequently tissue damage which could
affect subsequent readings in the absence of stimuli, the animals were removed from the
plate after 30 s exposure.
Procedure for Measurement:
Before any treatment was given, the latency time was measured in three successive
tests, carried out at intervals of 10 minutes. The average of the three measurements was
considered as being the "basal latency" value. After intraperitoneal administration, the test
latency times were re-measured at time intervals of 10 in 10 minutes, for 40 minutes.
The effects of the various treatments on the latency time were expressed as the Hot
Plate Analgesia Index-HPAI (Table I).
Drugs Utilised
Morphine hydrochloride and Sodium Dipyrone were used as standards.
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A 10 % hydroalcoholic solution was used to dilute the test compound, physiological
solution (NaCI 0,9%) was used to dissolve the standard compounds, and aqueous Tween 80
(10%) for hexacarbonyl chromium and pure anisole samples.
The doses for standards and tested compounds were shown in Table I.
Statistical Analysis
A statistical analysis was made usinj the t-Student and Anova methods for p<0.05.
Results and Discussion
In our preliminary studies we found that the reaction between Cr(CO)6 and anisole in
pure butyl acetate gives a low yield of the desired compound due to decomposition. The
substitution of butyl acetate by ethyl acetate, however, leads to incomplete reaction. The
use of decalin is not convenient for us, because this solvent can not be easily removed
under vacuum and flash chromatography would be necessary.
We combined the procedures of Mahaffy and Pauson and of Hudecek and
Toma’4’’7’ and carried out the reaction in a mixture of dibutyl ether with 5% of butyl
acetate or of ethyl acetate as coordinating co-solvent, adding the advantages of the
Mahaffy procedure (easily isolation) with these of Toma methods esters are more eficient as
co-solvents then THF), without the inconvenients of pure decalin. The need for special care
with the purity of reagents and solvents’4,’z’, was confirmed by us: the yields are very low
when impure solvents are used.
We also used a slow bubling of N into the reaction medium, during all the reflux
time, for removal of formed CO, because is well known that the reaction between a arene
and chromium hexacarbonyl is a equilibrium, and removal of the carbon monoxide is
necessary for complete reaction.
We used this modified procedure to obtain the qe-(anisole)-triscarbonyl- chromium(0)
complex used in this study. The same procedure was used for the synthesis of some other q-
(arene)-triscarbonyl-chromium(0) complexes(of the arenes" diethylphthalate, methvl benzoate,, mesitylene, toluene, benzene, chlorobenzene)
9 among these the new q
(diethylphthalate)-triscarbonyl-chromium(0) (Toma prepared the methyl analogue The
terephthalate analogue is known).
While various authors have prepared and studied arene chromium complexes, no
tests of biological activity were made.
On the other side, it was demonstrated that transition metal containing moieties(
such as chromium tricarbonyl), when coordinated to arenes have electron acceptor
properties6’7 and is also known that the analgesic activity of arenes is increased by the
presence of electron acceptor groupsz’’4’. For examples, anisole (this work) is a poor
analgesic, while phenacetin (4-acetylamino phenetole) is a powerfull analgesic. Aspirin
have a electron acceptor group (COOH) and also, the presence of a halogen (CI) atom in
analgesics increase their potency ,by increase of their efficiency as prostaglandin bio-
synthesis inhibitors.
These observations suggested to us that rle-(anisole)-triscarbonyl-chromium(0) may have
some degree of analgesic activity.
We carried out analgesic screening of qS-(anisole)-triscarbonyl-chromium(0), using
the Hot Plate algesimetric method
TM that demonstrate a supra-spinal response. We screened
30 and 50 mg/Kg doses ,injected through the intraperitoneal pathway.
As already mentioned, the analgesic measurements were continued during 40
minutes and expressed as the protection percent This short action time was selected
because the toxicology and side effects of administration of q6-(anisole)-triscarbonyl-
chromium(0) were unknown.
We observed that the both 30 and 50 mg/Kg doses showed a significant analgesic
effect when compared with these of the control group, and the standards(Table I).
These results suggests that qS-(anisole)-triscarbonyl-chromium(0) have analgesic
activity, higher then dipyrone, but not so high then morphine (Figure 1)
We also tested the precursors, anisole and hexacarbonyl chromium, and they seems
to be inactive, as expected, since they not possesses electron acceptor substituents.
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TABLE I. ANALGESIC EFFECT OF q-(ANISOLE)-TRISCARBONYL-CHROMIUM(0) (ATC),
EXPRESSED AS PROTECTION PERCENT
is
HPAI
TEST LATENCY BASAL LATENCY
x I00
*30 BASAL LATENCY
Sample Dose Reaction Time (HPAI)
mg/Kg
10 20 30 40
Control 03 -08 -03 00
ATC** 30 49 52 67 67
ATC** 50 50 65 75 75
Saline -02 -05 -07 -12
Morphine 04 93 81 100 65
Dipyrone 60 24 24 13 37
Tw80 10% 00 05 03 00
HCC*** 50 13 -06 -06 11
Anisole 50 -10 04 -10 -12
ATC is q-(anisole)-triscarbonyl-chromium(lll)












ContHA is the 10 % hydroalcoholic solution, ATC30 and 50 refers to 30 mg/Kg and 50 mg/Kg doses of
q6-(anisole)triscarbonyl-chromium (111)" saline is standard physiological solution (0.9 %), Morphine and
Dipyrone are the standards, HCC50 and Anisole50 refer to Hexacarbonyl chromium 30 mg/Kg and
anisole 50 mg/Kg, respectively. Tw80 10% refer to their control group.
Conclusion
We report a modified method for the synthesis of q-(anisole)-triscarbonyl-
chromium(0) and of some other arene tricarbonyl chromium complexes. Screening shows
that this compound exhibits high analgesic effect, the first ever reported for an organo-
metallic complex.
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